Genzyme of Cambridge, Massachusetts, faces millions in lost revenue from its top-selling specialty drugs Cerezyme and Fabrazyme as result of a viral contamination at its Allston, Massachusetts plant.

Genzyme originally launched Ceredase (placenta-derived GCR) in 1991, which was followed by the approval of Cerezyme (recombinant GCR) in 1994. Since that time, sales have grown steadily at a 28% ...